Finance

Nordic Capital-led consortium raises takeover price for Bavarian Nordic to $39 per share

Published by Global Banking & Finance Review

Posted on October 15, 2025

2 min read

· Last updated: January 21, 2026

Add as preferred source on Google
Nordic Capital-led consortium raises takeover price for Bavarian Nordic to $39 per share
Global Banking & Finance Awards 2026 — Call for Entries

(Reuters) -Bavarian Nordic said on Wednesday a consortium led by Nordic Capital and Permira has raised its offer price for the vaccine maker to 250 Danish crowns ($38.94) after its initial bid was not

Nordic Capital Consortium Increases Bavarian Nordic Offer to $39 per Share

Details of the Takeover Offer

(Reuters) -Bavarian Nordic said on Wednesday a consortium led by Nordic Capital and Permira had raised its offer price for the vaccine maker to 250 Danish crowns ($39) per share after its initial bid was not accepted by a sufficient number of investors.

Initial Offer and Board Recommendation

Innosera, a newly formed entity controlled by the consortium, had offered to buy Bavarian Nordic in July for 233 crowns per share, or around $3 billion in total, with the biotech's board unanimously recommending the offer to its shareholders in August.

Shareholder Response and Acceptance Rates

The board reiterated its recommendation of the offer in a statement on Thursday.

Future Plans for Bavarian Nordic

Bavarian Nordic's stock, which had closed at 230.5 crowns the night before, opened about 4.5% higher.

However, shareholders representing only about 25.7% of Bavarian Nordic's share capital have so far accepted the offer, according to Wednesday's statement. This is below the revised 75% threshold the consortium had.

Danish pension fund ATP's position on the offer remains unchanged, its Deputy Director of Danish Equities Claus Moller Berner told Reuters. The fund, which holds an around 10% stake in the vaccine maker based on LSEG data, had publicly rejected the previous offer.

Innosera has now informed Bavarian Nordic that the revised offer, which will expire on November 5, is its "best and final" and will not be increased further, the company said.

Bavarian Nordic, which makes mpox and other vaccines, is a key supplier to governments globally, including public health preparedness programmes in the United States.

The consortium plans to delist the company from Nasdaq Copenhagen following completion of the offer, which is expected in the fourth quarter of 2025.

($1 = 6.4075 Danish crowns)

(Reporting by Harshita Meenaktshi in Bengaluru and Vera Dvorakova in Gdansk; Editing by Leroy Leo and Milla Nissi-Prussak)

Key Takeaways

  • Nordic Capital raises Bavarian Nordic offer to $39 per share.
  • Initial offer was not accepted by enough investors.
  • Bavarian Nordic's stock rose 4.5% after the announcement.
  • Danish pension fund ATP maintains its rejection of the offer.
  • Consortium plans to delist Bavarian Nordic from Nasdaq Copenhagen.

Frequently Asked Questions

What is a takeover offer?
A takeover offer is a proposal made by an individual or company to purchase another company, usually at a premium over its current market price.
What is equity?
Equity represents ownership in a company, typically in the form of shares. Shareholders benefit from the company's profits and have voting rights.
What is a consortium?
A consortium is a group of individuals or organizations that come together to undertake a specific project or business venture, sharing resources and risks.
What is a shareholder?
A shareholder is an individual or institution that owns shares in a company, entitling them to a portion of the company's profits and assets.
What is a board recommendation?
A board recommendation is a formal suggestion made by a company's board of directors regarding a specific action, such as accepting a takeover offer.

Tags

Related Articles

More from Finance

Explore more articles in the Finance category